Dermatologic changes after systemic cancer therapy.
Dermatologic changes associated with systemic cancer therapy are common. These changes can be conveniently grouped into three clinical categories: 1) cytotoxic effects; 2) pigment alterations; and 3) rashes and eruptions. The clinician should be alert to these manifestations so that needless work-up is avoided..
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D003603:Cytotoxins / Q000009:adverse effects; D003609:Dactinomycin / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects; D010859:Pigmentation Disorders / Q000139:chemically induced
D000970:Antineoplastic Agents; D003603:Cytotoxins; D001761:Bleomycin; D003609:Dactinomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate